Physician profile
Charles R Smith
NPI 1700959426
$345,889.78
in general payments reported to CMS, 2019-2025
54 companies · $22.91 in 2025
The $22.91 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145K · 2020: $58K · 2021: $36K · 2022: $78K · 2023: $29K · 2025: $22.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Honoraria: $7,700 · Food and Beverage: $2,971 · Travel and Lodging: $1,666 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,435.00 |
| Honoraria | $7,700.00 |
| Food and Beverage | $2,970.92 |
| Travel and Lodging | $1,666.44 |
| Education | $107.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $106,433.11 | 2019-2023 | Tysabri, Vumerity |
| Emd Serono, INC. | $73,504.77 | 2019-2023 | Mavenclad |
| Horizon Therapeutics Plc | $35,091.54 | 2021-2023 | Uplizna |
| Genzyme Corporation | $31,001.66 | 2019-2023 | |
| Genentech USA, INC. | $27,980.46 | 2019-2023 | Ocrevus |
| Celgene Corporation | $27,327.18 | 2019-2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $17,243.22 | 2019-2023 | Soliris, Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $11,258.89 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $8,557.07 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $1,974.60 | 2021-2022 | |
| Genentech, INC. | $1,252.31 | 2019-2023 | Ocrevus |
| Abbvie INC. | $909.12 | 2020-2023 | Botox, Qulipta, Ubrelvy |
| Amgen INC. | $422.22 | 2019-2022 | |
| Allergan, INC. | $254.78 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $228.58 | 2019-2021 |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.